☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
Fresenius Kabi Reports the Reguatory Submission to the US FDA for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram
November 22, 2024
Xenetic Biosciences Reports Preclinical Data of Potential Co-Administration of DNase I with CAR T Cells for Melanoma Lung Metastasis
November 22, 2024
5 Steps to Take After an Injury from a Defective Product
November 22, 2024
Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B
November 22, 2024
The importance of pediatric dentistry in child health for Edina residents
November 22, 2024
Alloy Therapeutics Inks a Pact with Takeda to Develop Cell Therapy Platform
November 21, 2024
Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites
November 20, 2024
Xbrane Biopharma and Intas Pharmaceuticals Join Forces to Develop Biosimilar of Opdivo (Nivolumab)
November 20, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
